Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Living Cell Technologies ( (AU:1AI) ) has shared an announcement.
Algorae Pharmaceuticals Ltd has made significant strides in the September 2025 quarter, marked by strategic partnerships and advancements in its AI drug discovery platform. The company executed a licensing agreement with Sakar Healthcare Ltd for five oncology generics and signed a binding term sheet with Cadila Pharmaceuticals Ltd for two generic medicines targeting cardiovascular and metabolic disorders. These partnerships expand Algorae’s commercial portfolio and reinforce its strategy of combining AI-powered drug discovery with pharmaceutical distribution. Additionally, Algorae advanced its proprietary AI platform, AlgoraeOS, and continued pre-clinical development of its therapeutic candidates, AI-116 and AI-168, positioning the company for future growth and innovation in the pharmaceutical industry.
More about Living Cell Technologies
Algorae Pharmaceuticals Ltd is an AI-enabled pharmaceutical development company focused on AI-driven innovation and pharmaceutical commercialization. The company is expanding its operations in Australia and New Zealand, with a focus on oncology, cardiovascular, and metabolic markets.
Average Trading Volume: 2,864,215
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$16.87M
For detailed information about 1AI stock, go to TipRanks’ Stock Analysis page.